Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients With Advanced Non-Small Cell Lung Cancer in Tropion-Lung02 Phase Ib Trial
June 07, 2023
June 07, 2023
WILMINGTON, Delaware, June 7 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Updated results from the TROPION-Lung02 Phase Ib trial showed, with additional enrolment and follow-up from the initial presentation, that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum-based chemotherapy demonstrated promising clinical activity and no new safety signals in both previously untreated or pretreated patients . . .
Updated results from the TROPION-Lung02 Phase Ib trial showed, with additional enrolment and follow-up from the initial presentation, that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum-based chemotherapy demonstrated promising clinical activity and no new safety signals in both previously untreated or pretreated patients . . .